Literature DB >> 20151718

Identification of novel protein kinase A phosphorylation sites in the M-domain of human and murine cardiac myosin binding protein-C using mass spectrometry analysis.

Weitao Jia1, Justin F Shaffer, Samantha P Harris, Julie A Leary.   

Abstract

Cardiac myosin binding protein-C (cMyBP-C) is a large multidomain accessory protein bound to myosin thick filaments in striated muscle sarcomeres. It plays an important role in the regulation of muscle contraction, and mutations in the gene encoding cMyBP-C are a common cause of familial hypertrophic cardiomyopathy, the leading cause of sudden cardiac death in young people. (1) The N-terminal domains including the C0, C1, cMyBP-C motif, and C2 domains play a crucial role in maintaining and modulating actomyosin interactions (keeping normal cardiac function) in a phosphorylation-dependent manner. The cMyBP-C motif or "M-domain" is a highly conserved linker domain in the N-terminus of cMyBP-C that contains three to five protein kinase A (PKA) phosphorylation sites, depending on species. For the human isoform, three PKA sites were previously identified (Ser(275), Ser(284), and Ser(304)), while three homologous sites exist in the murine isoform (Ser(273), Ser(282), and Ser(302)). The murine cMyBP-C isoform contains an additional conserved consensus site, Ser(307) that is not present in the human isoform. In this study, we investigated sites of PKA phosphorylation of murine and human cMyBP-C by treating the recombinant protein C0C2 ( approximately 50 KDa, which contains the N-terminal C0, C1, M, and C2 domains) and C1C2 (approximately 35 KDa, contains C1, M, and C2 domains) with PKA and assessing the phosphorylation states using SDS-PAGE with ProQ Diamond staining, and powerful hybrid mass spectrometric analyses. Both high-accuracy bottom-up and measurements of intact proteins mass spectrometric approaches were used to determine the phosphorylation states of C0C2 and C1C2 proteins with or without PKA treatment. Herein, we report for the first time that there are four PKA phosphorylation sites in both murine and human M-domains; both murine Ser(307) and a novel human Ser(311) can be phosphorylated in vitro by PKA. Future studies are needed to investigate the phosphorylation state of murine and human cMyBP-C in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20151718      PMCID: PMC3000796          DOI: 10.1021/pr901006h

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  47 in total

Review 1.  Detection and localization of protein modifications by high resolution tandem mass spectrometry.

Authors:  Fanyu Meng; Andrew J Forbes; Leah M Miller; Neil L Kelleher
Journal:  Mass Spectrom Rev       Date:  2005 Mar-Apr       Impact factor: 10.946

2.  Phosphorylation analysis by mass spectrometry: myths, facts, and the consequences for qualitative and quantitative measurements.

Authors:  Hanno Steen; Judith A Jebanathirajah; John Rush; Nicolas Morrice; Marc W Kirschner
Journal:  Mol Cell Proteomics       Date:  2005-10-04       Impact factor: 5.911

3.  Top down mass spectrometry of < 60-kDa proteins from Methanosarcina acetivorans using quadrupole FRMS with automated octopole collisionally activated dissociation.

Authors:  Steve M Patrie; Jonathan T Ferguson; Dana E Robinson; Dave Whipple; Michael Rother; William W Metcalf; Neil L Kelleher
Journal:  Mol Cell Proteomics       Date:  2006-01       Impact factor: 5.911

Review 4.  Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes.

Authors:  Jil C Tardiff
Journal:  Heart Fail Rev       Date:  2005-09       Impact factor: 4.214

5.  Mass spectrometric analysis of the human 40S ribosomal subunit: native and HCV IRES-bound complexes.

Authors:  Yonghao Yu; Hong Ji; Jennifer A Doudna; Julie A Leary
Journal:  Protein Sci       Date:  2005-05-09       Impact factor: 6.725

6.  Quantitative phosphoproteomics applied to the yeast pheromone signaling pathway.

Authors:  Albrecht Gruhler; Jesper V Olsen; Shabaz Mohammed; Peter Mortensen; Nils J Faergeman; Matthias Mann; Ole N Jensen
Journal:  Mol Cell Proteomics       Date:  2005-01-22       Impact factor: 5.911

7.  cAPK-phosphorylation controls the interaction of the regulatory domain of cardiac myosin binding protein C with myosin-S2 in an on-off fashion.

Authors:  M Gruen; H Prinz; M Gautel
Journal:  FEBS Lett       Date:  1999-06-25       Impact factor: 4.124

8.  Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns.

Authors:  Martin R Larsen; Tine E Thingholm; Ole N Jensen; Peter Roepstorff; Thomas J D Jørgensen
Journal:  Mol Cell Proteomics       Date:  2005-04-27       Impact factor: 5.911

9.  Cardiac myosin-binding protein-C phosphorylation and cardiac function.

Authors:  Sakthivel Sadayappan; James Gulick; Hanna Osinska; Lisa A Martin; Harvey S Hahn; Gerald W Dorn; Raisa Klevitsky; Christine E Seidman; Jonathan G Seidman; Jeffrey Robbins
Journal:  Circ Res       Date:  2005-10-13       Impact factor: 17.367

10.  Ablation of myosin-binding protein-C accelerates force development in mouse myocardium.

Authors:  Julian E Stelzer; Daniel P Fitzsimons; Richard L Moss
Journal:  Biophys J       Date:  2006-03-02       Impact factor: 4.033

View more
  44 in total

1.  A gain-of-function mutation in the M-domain of cardiac myosin-binding protein-C increases binding to actin.

Authors:  Kristina L Bezold; Justin F Shaffer; Jaskiran K Khosa; Elaine R Hoye; Samantha P Harris
Journal:  J Biol Chem       Date:  2013-06-19       Impact factor: 5.157

2.  The contribution of cardiac myosin binding protein-c Ser282 phosphorylation to the rate of force generation and in vivo cardiac contractility.

Authors:  Kenneth S Gresham; Ranganath Mamidi; Julian E Stelzer
Journal:  J Physiol       Date:  2014-06-20       Impact factor: 5.182

3.  The motif of human cardiac myosin-binding protein C is required for its Ca2+-dependent interaction with calmodulin.

Authors:  Yanling Lu; Ann H Kwan; Cy M Jeffries; J Mitchell Guss; Jill Trewhella
Journal:  J Biol Chem       Date:  2012-07-16       Impact factor: 5.157

4.  Phosphorylation and calcium antagonistically tune myosin-binding protein C's structure and function.

Authors:  Michael J Previs; Ji Young Mun; Arthur J Michalek; Samantha Beck Previs; James Gulick; Jeffrey Robbins; David M Warshaw; Roger Craig
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-23       Impact factor: 11.205

5.  Direct visualization of myosin-binding protein C bridging myosin and actin filaments in intact muscle.

Authors:  Pradeep K Luther; Hanspeter Winkler; Kenneth Taylor; Maria E Zoghbi; Roger Craig; Raúl Padrón; John M Squire; Jun Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-24       Impact factor: 11.205

Review 6.  Proteomics in heart failure: top-down or bottom-up?

Authors:  Zachery R Gregorich; Ying-Hua Chang; Ying Ge
Journal:  Pflugers Arch       Date:  2014-03-13       Impact factor: 3.657

7.  The myosin mesa and the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations.

Authors:  Suman Nag; Darshan V Trivedi; Saswata S Sarkar; Arjun S Adhikari; Margaret S Sunitha; Shirley Sutton; Kathleen M Ruppel; James A Spudich
Journal:  Nat Struct Mol Biol       Date:  2017-05-08       Impact factor: 15.369

Review 8.  Oxidative stress and sarcomeric proteins.

Authors:  Susan F Steinberg
Journal:  Circ Res       Date:  2013-01-18       Impact factor: 17.367

9.  Phosphorylation modulates the mechanical stability of the cardiac myosin-binding protein C motif.

Authors:  Arthur J Michalek; Jack W Howarth; James Gulick; Michael J Previs; Jeffrey Robbins; Paul R Rosevear; David M Warshaw
Journal:  Biophys J       Date:  2013-01-22       Impact factor: 4.033

Review 10.  Proteomics-based methods for discovery, quantification, and validation of protein-protein interactions.

Authors:  Yana V Miteva; Hanna G Budayeva; Ileana M Cristea
Journal:  Anal Chem       Date:  2012-12-12       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.